



BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Government of India)

No. BPPI/Drug- 055/2017

Dated: 13/10/2018

ORDER

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi had published tender no. BPPI/Drugs- 055/2017 dated 18.12.2017 through e-procurement system for supply of drugs for the year 2017-2019.

Whereas, M/S GKM New Pharma (here after called as the firm) addressed at "Spl. Type Plot No. 5,6,7&8, PIPDIC Electronic Park, Thirubuvanai, Mannadipet Commune", Puducherry- 605107, India, had participated in tender. The firm was awarded 04 drugs by Bureau of Pharma Public Sector Undertakings of India, New Delhi vide Letter of acceptance dated 08/05/2018 for the period of 2 years as per tender provision. The firm was asked to supply the drug within 45 days against 1st purchase order and 30 days against subsequent order as per clause 12.4 (a), (b) of tender document as per details below:-

S. No.	Purchase order no. & date	Drug code	Description of Drug	Quantity	Delivery Period	Value of purchase order(Including GST)
1.	18000541 dated 03.08.18	840	Citicoline Tablets 500mg	33000	45 Days (Expired on 17.09.2018)	2665186/-
2.	18000795 dated 10.09.18	840	Citicoline Tablets 500mg	22000	30 Days (Expired on 10.10.2018)	1776790/-

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi issued Show cause notice on 10/09/2018 to the firm informing about provisions of the clause no. 11 (e), 19.7 & 20.1(a) of tender document with request to explain within 7 days why not following actions against them may be taken:-

- Forfeit of Security Deposit of Rs. 3318420/- submitted by you in form of Bank Guarantee No. 839GPGE181440004 dated 24.05.2018 from Canara Bank.
- Consider your bad performance for future dealings & disqualify your company from participating in the tender for the 2 years.
- Recover 5% value of supply order from your pending bill.
- Initiate blacklisting of your company.


Whereas, the firm vide their e-mail dated 26/09/2018 informed that they couldn't supply DC-840 against the PO No. 18000541 dated: 03.08.18 and due to short supply of raw material. Further, the firm vide their another e-mail dated 8/10/2018 have also informed that they are unable to supply same drug against PO No. 18000795 dated 10.09.2018 as API material of citicoline is under short supply/ not available. The firm's

Continued -

justification for non-supply of drug due to shortage of raw material is not covered under tender terms & conditions and not acceptable to BPPI in terms of tender provision.

In view of above, the firm is debarred for a period of 2 years to participate in the tender of Bureau of Pharma Public Sector Undertakings of India, New Delhi for supply of DC- 840 (Citicoline Tablets 500mg) from date of issuance of this order besides recovery of 5% value of supply order from pending bills & forfeiture of performance security.

This order is without prejudice to the legal and criminal action to be taken if any, by Bureau of Pharma Public Sector Undertakings of India, New Delhi in the matter.


(Sachin Singh, IRS)
Chief Executive Officer
Bureau of Pharma PSUs of India, New Delhi

To

Regd.

M/S GKM New Pharma (here after called as the firm) addressed at "Spl. Type Plot No. 5,6,7&8, PIPDIC Electronic Park, Thirubuvanai, Mannadipet Commune", Puducherry- 605107, India